** Brokerage UBS upgrades medical imaging maker GE HealthCare GEHC.O to "neutral" from "sell", cuts PT to $69 from $75

** New PT still implies an over 6% upside to the stock's last close

** UBS says the stock has already fallen about 30% since January and now looks cheap enough to reflect many of the risks

** Notes that GEHC still has several issues to work through, and brokerage does not see strong near-term catalysts to push the stock meaningfully higher

** Brokerage says concerns remain over margin pressure from inflation, China's recovery in 2027, Omnipaque facing generic competition and whether diagnostic device Flyrcado can hit its $500 million 2028 sales target

** Including the session's move, GEHC stock down 21.7% YTD